Bahl & Gaynor Inc. Sells 189,941 Shares of Zoetis Inc. $ZTS

Bahl & Gaynor Inc. trimmed its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 91.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,870 shares of the company’s stock after selling 189,941 shares during the quarter. Bahl & Gaynor Inc.’s holdings in Zoetis were worth $2,468,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC grew its stake in Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after acquiring an additional 2,978 shares in the last quarter. Empowered Funds LLC boosted its holdings in shares of Zoetis by 6.2% in the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock valued at $1,859,000 after purchasing an additional 657 shares during the period. Intech Investment Management LLC grew its stake in Zoetis by 17.2% in the first quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after purchasing an additional 1,224 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Assetmark Inc. raised its position in Zoetis by 12.2% during the 2nd quarter. Assetmark Inc. now owns 26,409 shares of the company’s stock valued at $4,119,000 after purchasing an additional 2,876 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

ZTS stock opened at $128.95 on Tuesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The firm has a market cap of $54.43 billion, a price-to-earnings ratio of 21.42, a PEG ratio of 2.00 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm has a 50-day simple moving average of $126.16 and a two-hundred day simple moving average of $133.75.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. Zoetis’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.6%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZTS. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday. JPMorgan Chase & Co. cut their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 price target on shares of Zoetis in a research report on Thursday. Finally, Stifel Nicolaus cut their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a report on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.